Rinvoq (Upadacitinib)

Save 50% on Rinvoq from Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Abbvie manufactures Rinvoq in the following manufacturing sites for Europe: AbbVie S.r.l. S.R. 148 Pontina, km 52 SNC 04011 Campoverde di Aprilia (Latina) Italy AbbVie Logistics B.V. Zuiderzeelaan 53 Zwolle, 8017 JV, Netherlands

Information about Rinvoq (Upadacitinib)

Rinvoq is the brand name for Upadacitinib, a Janus kinase (JAK) inhibitor manufactured by AbbVie. It is an oral medication used to treat several inflammatory conditions by targeting and inhibiting specific enzymes that contribute to the inflammatory process. Upadacitinib selectively inhibits JAK1, an enzyme involved in immune cell signaling, helping to reduce inflammation and immune response in conditions such as rheumatoid arthritis, atopic dermatitis, and ulcerative colitis.

Product Highlights

• For the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
• For adults and adolescents with moderate to severe atopic dermatitis (eczema) who do not respond adequately to topical treatments.
• For adults with moderate to severe ulcerative colitis who have not responded well to other medications, such as TNF inhibitors.
• Rinvoq may also be used for ankylosing spondylitis, a type of inflammatory arthritis affecting the spine.

Key Ingredient

• Upadacitinib

Key Benefits

• Rinvoq provides relief for patients suffering from chronic inflammatory diseases, including rheumatoid arthritis and atopic dermatitis.
• Unlike some biologics that require injections, Rinvoq is taken in pill form once daily, making it easier for patients to adhere to their treatment regimen.
• Studies show that Rinvoq can help reduce symptoms like pain, swelling, and redness relatively quickly compared to traditional therapies.
• By reducing inflammation and managing symptoms, Rinvoq can significantly improve the quality of life for patients with chronic conditions like RA and eczema.
• The selective inhibition of JAK1 helps specifically target the pathway involved in immune response and inflammation, which can reduce side effects compared to broader immune suppressive treatments.

Direction of Use

• The typical dosage of Rinvoq varies depending on the condition being treated:
• The usual dose is 15 mg once daily. In some cases, a dose of 30 mg once daily may be prescribed if necessary.
• The recommended dose is 15 mg once daily for adults.
• The initial dose is typically higher (30 mg once daily) for the first 8 weeks, followed by a maintenance dose of 15 mg once daily.
• The recommended dose is usually 15 mg once daily.
• Rinvoq is administered as an oral tablet and can be taken with or without food. 
• It is important for patients to take Rinvoq exactly as prescribed and not to skip doses for optimal effectiveness.

Safety Concerns

• Because Rinvoq suppresses the immune system, it increases the risk of serious infections, including tuberculosis (TB), bacterial, fungal, and viral infections. Patients should be tested for TB before starting Rinvoq.
• There is a potential risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), especially in patients with a history of these conditions.
• Long-term use of JAK inhibitors like Rinvoq may increase the risk of certain cancers, including lymphoma and skin cancer.
• Rinvoq can cause liver damage. Regular liver function tests are recommended to monitor for signs of liver toxicity.
• Patients with a history of heart disease may experience increased risks, including heart attacks or other cardiovascular issues.
• Common side effects may include headache, nausea, acne, elevated blood pressure, and upper respiratory infections. 

Avoid Rinvoq (Upadacitinib) If

• Rinvoq should be avoided in patients with active infections, as it may exacerbate the condition or increase the risk of complications.
• Patients who have a history of blood clots (e.g., deep vein thrombosis, pulmonary embolism) or stroke should avoid Rinvoq or use it with caution.
• Rinvoq is contraindicated in patients with moderate to severe liver impairment or active liver disease due to the risk of further liver damage.
• Patients with a history of cancer (except for certain non-melanoma skin cancers) should avoid Rinvoq due to the potential increased risk of malignancies.
• Rinvoq is not recommended during pregnancy or breastfeeding unless absolutely necessary. It may harm the fetus or pass into breast milk, affecting the infant.
• Live vaccines should be avoided during treatment with Rinvoq, as the immunosuppressive effects of the drug may interfere with the vaccine's effectiveness or increase the risk of infection.